LOGIN OR REGISTER
Course Library

NLA- SAP Module 5- Contemporary Management of Dyslipidemia: Pharmacologic Therapy

Cardiology
Credits:
16.25 AMA PRA Category 1 Credit(s) ™ 16.1 ANCC Contact Hours 16.25 ACPE 16 CDR
Launch Date:
November 15, 2016
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

Lipidologists, Lipid Specialists, Cardiologists, Endocrinologists, Internists, Nephrologists, Primary Care Physicians, Family Practitioners, PhDs, Physicians Assistants, Cardiovascular Nurses, Nurse Practitioners, Pharmacists, Dietitians

Relevant Terms:

Pharmacologic Therapy

See Faculty section below for a complete list of faculty.

See Faculty section below for a complete list of faculty.

1. Recognize the role of drug therapy in the management of dyslipidemia.
2. Discuss the impact of lipid medication on lipoprotein metabolism.
3. Review the mechanism of action, pharmacokinetics, and efficacy of available FDA approved drugs for the management of lipid disorders.
4. Review clinical trials of lipid-altering drug therapies used in cardiovascular disease prevention.
5. Assess the side effects of lipid-altering drugs to encourage their safe use in cardiovascular disease prevention.
6. Describe combination therapies for the management of complex lipid disorders and residual risk.
7. Describe the appropriate use of lipid-altering drugs in special populations.
8. Assess the status of new and emerging treatment options for cholesterol and triglyceride management.
9. Review representative clinical cases in the management of patients with dyslipidemia.

CRITERIA FOR SUCCESS
In order to receive credit for this enduring program, participants must answer each question, review the ensuing critiques and evaluate the activity. A statement of credit will be available upon completion of an evaluation form. If you have questions about this CME/ CE activity, please contact the NLA at cme@lipid.org.
 
For Pharmacists: Upon receipt of the completed activity evaluation form, transcript information will be available at www.mycpemonitor.net within 4 weeks.
 
Physicians who complete a program evaluation will receive a Statement of Continuing Education Credit from the NLA for up to 16.25 hours of AMA PRA Category 1 Credits™ toward the AMA Physician Recognition Award. To receive credit you must obtain a 30% or greater total score on your Performance Score Report.
 
COMMERCIAL SUPPORT
There is no commercial support for this activity.
 
CREDIT DESIGNATION
CME credit provided by the National Lipid Association
The National Lipid Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The National Lipid Association designates this enduring activity for a maximum of 16.25 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in this activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

Dietitians
The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 16 continuing professional education units (CPEUs) for completion of this program/ materials. CDR Accredited Provider #NL002.
 
CE Credit provided by Postgraduate Institute for Medicine
 
Pharmacists
Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Universal Activity Number 0809-9999-16-458-H01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 16.25 contact hour(s) (1.625 CEUs) of the Accreditation Council for Pharmacy Education

Nursing
This educational activity for 16.1 contact hours is provided by the Postgraduate Institute for Medicine.
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

For the advanced practice nurse, this activity has 1.2 contact hours of pharmacotherapy content.
 
This self-assessment program is recognized for Maintenance of Certification by the American Board of Clinical Lipidology and Renewal of Certification by the Accreditation Council for Clinical Lipidology.
 
FACULTY
Editor-in-Chief
Carl E. Orringer, MD, FNLA*
Associate Professor of Medicine
University of Miami Miller School of Medicine
Miami, FL
 
Associate Editor
Joseph J. Saseen, PharmD, FNLA†
Professor and Vice Chair, Department of Clinical Pharmacy
Professor, Department of Family Medicine
University of Colorado Anschutz Medical Campus
Aurora, CO
 
Contributing Editors
Daniel E. Soffer, MD, FNLA*
Clinical Associate Professor of Medicine
University of Pennsylvania Health System
Internal Medicine/Clinical Lipidology
Media, PA
 
Barbara S. Wiggins, PharmD, FNLA†
Clinical Pharmacy Specialist – Cardiology
Medical University of South Carolina
Adjunct Professor
Medical University of South Carolina College of Pharmacy
Charleston, SC
 
*Denotes Diplomate, American Board of Clinical Lipidology.
†Denotes Diplomate, Accreditation Council for Clinical Lipidology.
 
DISCLOSURES
Carl E. Orringer, MD, FNLA has nothing to disclose.
 
Joseph J. Saseen, PharmD, FNLA has nothing to disclose.
 
Daniel E. Soffer, MD, FNLA has received support for clinical research from Amgen, AstraZeneca, Ionis Pharmaceuticals, Novartis, Pfizer, Regeneron Pharmaceuticals, and sanofi-aventis U.S. He served as a clinical science advisor for Global Organization for EPA and DHA Omega-3s (GOED).
 
Barbara S. Wiggins, PharmD, FNLA has nothing to disclose.
 
Reviewer:
Nicole Woodsmall, MSH, RDN has nothing to disclose.
 
CME Reviewer:
Donald G. Lamprecht, PharmD, FNLA has nothing to disclose.
 
NLA staff has nothing to disclose.
PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN, and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
 
DISCLOSURE OF UNLABELED USE AND INVESTIGATIONAL PRODUCT
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
 
DISCLOSURE DECLARATION
It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. Planners, faculty, reviewers, and staff have disclosed any financial relationships with commercial interests as defined by the ACCME. 
 
DISCLAIMER
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader’s misunderstanding of content.
 
 
COURSE VIEWING REQUIREMENTS
Supported Browsers:
Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
 		 Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.



 

Schedule an event with a Standardized Patient
×